Table 1.
Summary of the demographics and clinical data for patients with laryngeal involvement with plasma cell myeloma identified in the retrospective analysis.
| Patient | Age (Years) |
Sex | Type of Disease | Localisation | Symptoms | Surgery | RTX Dose (cGy) | CTH | PFS from Larynx Involvement (mo) | Survival Form Larynx Involvement (mo) |
Death | OS (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | 70 | M | sEMPL | 1 | 1, 2, 3 | 0 | 5000 | 0 | 18 | 18 | 0 | NA |
| Patient 2 | 59 | M | sEMPL | 1 | 0 | 0 | 4000 | 0 | 111 | 111 | 0 | NA |
| Patient 3 | 72 | F | PCM-L | 5 | 1, 3 | 0 | N | 1 | 0.75 | 0.75 | 1 | 42 |
| Patient 4 | 84 | M | PCM-L | 1 | 4 | 0 | 4000 | 1 | 14 | 14 | 1 | 33 |
| Patient 5 | 78 | M | PCM-L | 5 | 3 | 0 | N | 0 | 1.5 | 1.5 | 1 | 1.5 |
| Patient 6 | 89 | M | PCM-L | 4 | 3 | 0 | N | 0 | 2 | 2 | 1 | 2 |
sEMPL—solitary extramedullary plasmacytoma of the larynx; PCM-L—plasma cell myeloma with bone marrow and laryngeal involvement, NA—not applicable data; mo—months; M—male; F—female; RTX—radiotherapy; CTH—chemotherapy; PFS—progression-free survival; OS—overall survival; Localisation: 1—supraglottic, 4—supraglottic + glottic, 5—supraglottic + glottic + subglottic; Symptoms: 0—no symptoms, 1—hoarseness, 2—cough, 3—dyspnea, 4—localised pain; RTX: N—no radiotherapy; PFS-Larynx—PFS counted from laryngeal involvement; OS-Larynx—OS counted from laryngeal involvement; Surgery/CTH/Death: 1—yes, 0—no.